KALA BIO

Update in progress

KALA (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on therapies for rare and severe eye diseases. Its lead candidate KPI-012 is in Phase 2b testing for persistent corneal epithelial defects, limbal stem cell deficiency, and other rare corneal diseases. A preclinical program, KPI-014, targets rare inherited retinal diseases. Formerly Kala Pharmaceuticals, it rebranded in 2023 and is based in Arlington, Massachusetts.

Company score

Sentiment: 0.26; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.01; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.02; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.14; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive